North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growth of the world leading C. elegans CRO.

C. elegans is a proven model for toxicology research and has numerous advantages over other animal models

Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for ageing therapeutics.

Five Alarm Bio works with Magnitude Biosciences to develop therapeutics for age-related disease.

David Weinkove, CEO of Magnitude Biosciences joins New Matter

The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing researcher and entrepreneur David Weinkove, Associate Professor at the Department of Biosciences, Durham University and CEO of Magnitude Biosciences Ltd.

Michelin, a Fortune 500 consumer good manufacturing company and the global leader in tyre manufacturing, works with Magnitude Biosciences for a sustainable, ethical solution for whole organism toxicity testing.

Take a look at our Poster from ELRIG Drug Discovery 2021: Automated Monitoring of C. elegans Movement for Neurodegeneration and Ageing. Related Resources

Determine whether caloric restriction could be involved in your test compound's mode of action.

Just published in Frontiers in Aging: Applying C. elegans to industrial drug discovery